Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from product rentals and other services in Japan and APAC, as well as revenue from treatment services and other services in the United States, increased. Research and development expenses decreased due to the implementation of new product development, clinical research and contract research operations. Other selling, general and administrative expenses decreased due to cost reductions. Other income was attributable to foreign exchange gains and revenue from contract research operations, among other factors. Financial income was attributable to gains on the valuation of investment securities and interest received, among other factors.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥2,008 million (YoY +2.3%) |
| Operating profit | ¥-124 million |
| Ordinary income | ¥170 million (YoY -42.9%) |
| Profit attributable to owners of the parent | ¥54 million (YoY -22.5%) |
| Net income per share | ¥0.26 |
| Equity ratio | End of the current fiscal period 81 / End of previous period 80.7 |
| Total assets | ¥49,208 million |
| Net assets | ¥39,831 million |
| Cash flows from operating activities | ¥-44 million |
| Cash flows from investing activities | ¥4,063 million |
| Cash flows from financing activities | ¥-146 million |
| Cash and cash equivalents at end of period | ¥12,855 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason The earnings forecast has not been disclosed in numerical terms |
| Annual Dividend Forecast | 0.00 (actual for the fiscal year ended March 2026) → Not disclosed |
| Depreciation and amortization | 307 Millions of yen (depreciation and amortization) |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 215,145,809 shares issued at period-end |
| Treasury Shares at Period-End | 4,014,854 treasury shares at period-end |
| Factors Behind Changes in Business Performance | Revenue from product rentals and other services in Japan and APAC, as well as revenue from treatment services and other services in the United States, increased. Research and development expenses decreased due to the implementation of new product development, clinical research and contract research operations. Other selling, general and administrative expenses decreased due to cost reductions. Other income was attributable to foreign exchange gains and revenue from contract research operations, among other factors. Financial income was attributable to gains on the valuation of investment securities and interest received, among other factors. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from product rentals and other services in Japan and APAC, as well as revenue from treatment services and other services in the United States, increased. The reduction in the operating loss was attributable to lower research and development expenses and cost reductions, among other factors. With respect to interim profit attributable to owners of the parent, financial income, including gains on the valuation of investment securities and interest received, and deferred tax expenses are among the items disclosed.